Hisun Biomaterials released its 2026 interim report, showing net profit attributable to the parent company of 20.92 million yuan, up 557.61% from the same period last year. Total operating revenue reached 606 million yuan, up 48.53% year on year. Net cash inflow from operating activities was 26.39 million yuan, up 45.63% year on year, marking a second consecutive year of growth. The company's latest asset-liability ratio stood at 26.51%, gross margin at 13.13%, return on equity at 1.40%, and diluted earnings per share at 0.10 yuan.
Zhejiang HISUN Biomaterials Co. Ltd. ANet profit surged 557.61% year on year, with revenue up 48.53%.
